• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, March 6, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Nasal spray that protects against COVID-19 is also effective against the common cold

Bioengineer by Bioengineer
February 2, 2021
in Biology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Hunter Medical Research Institute

IMAGE

Credit: Hunter Medical Research Institute

Research into a new drug which primes the immune system in the respiratory tract and is in development for COVID-19 shows it is also effective against rhinovirus. Rhinovirus is the most common respiratory virus, the main cause of the common cold and is responsible for exacerbations of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. In a study recently published in the European Respiratory Journal (LINK), the drug, known as INNA-X, is shown to be effective in a pre-clinical infection model and in human airway cells.

Treatment with INNA-X prior to infection with rhinovirus significantly reduced viral load and inhibited harmful inflammation.

University of Newcastle and Hunter Medical Research Institute (HMRI) researcher Associate Professor Nathan Bartlett, who led the study, said INNA-X showed great promise as a new way to protect people from diseases caused by common respiratory viruses such as rhinovirus. These diseases range from the common cold to potentially life-threatening exacerbations of chronic respiratory diseases, which cost the global economy billions of dollars each year.

“Consistent with what we have reported for other respiratory viruses including SARS-CoV-2 (the virus that causes COVID-19), INNA-X treatment prior to infection reduced the level of virus in the respiratory tract,” Associate Professor Bartlett said.

“We have also examined the effect of INNA-X in airway cells from patients with asthma which we know have a less effective anti-viral immune response and found that INNA-X treatment was effective providing a rationale for the use of INNA-X in at risk populations.”

INNA-X is developed by the Australian biotech company Ena Respiratory and works by stimulating the innate immune system in the airways, the first line of defense against the invasion of respiratory viruses into the body. This immune priming makes it much more difficult for viruses such as rhinoviruses to take hold, cause serious symptoms and spread.

INNA-X has been also shown to be highly effective at reducing virus shedding of SARS-CoV-2 and human trials of Ena Respiratory’s clinical candidate INNA-051 will begin in Australia in the coming weeks.

“If found protective, this could be used by at risk populations including elderly or asthma patients, to reduce the severity of rhinovirus, COVID-19 and other respiratory viruses’ infections in conjunction with vaccine approaches,” Associate Professor Bartlett said.

###

* HMRI is a partnership between the University of Newcastle, Hunter New England Health, and the community.

About Ena Respiratory

Ena Respiratory is aiming to transform the treatment and prevention of respiratory infections, including COVID-19 in at-risk populations.

Ena Respiratory is developing novel, synthetic innate immunomodulators for the prevention of respiratory viral and bacterial infections. The company is based in Melbourne and Sydney, Australia.

Media Contact
Sam Cardwell
[email protected]

Original Source

https://hmri.org.au/news-article/research-shows-nasal-spray-protects-against-covid-19-also-effective-against-common-cold

Related Journal Article

http://dx.doi.org/10.1183/13993003.01584-2020

Tags: Clinical TrialsImmunology/Allergies/AsthmaInfectious/Emerging DiseasesInternal MedicineMedicine/HealthPharmaceutical SciencePulmonary/Respiratory MedicineVaccinesVirology
Share14Tweet9Share2ShareShareShare2

Related Posts

IMAGE

What can stream quality tell us about quality of life?

March 5, 2021
IMAGE

Species traded legally through Hong Kong with inadequate traceability

March 5, 2021

Switzerland’s energy transition

March 5, 2021

‘Falling insect’ season length impacts river ecosystems

March 5, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    668 shares
    Share 267 Tweet 167
  • People living with HIV face premature heart disease and barriers to care

    84 shares
    Share 34 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    39 shares
    Share 16 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    36 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Climate ChangecancerMaterialsCell BiologyChemistry/Physics/Materials SciencesBiologyTechnology/Engineering/Computer ScienceInfectious/Emerging DiseasesPublic HealthEcology/EnvironmentMedicine/HealthGenetics

Recent Posts

  • “Magic sand” might help us understand the physics of granular matter
  • Study reveals how egg cells get so big
  • Survey identifies factors in reducing clinical research coordinator turnover
  • New ‘split-drive’ system puts scientists in the (gene) driver seat
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In